US Patent Issued to INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Universite Paul Sabatier Toulouse III, Icahn School of Medicine at Mount Sinai on Dec. 23 for "EPAC1 inhibitors for the treatment of idiopathic pulmonary fibrosis" (American, French Inventors)

ALEXANDRIA, Va., Dec. 23 -- United States Patent no. 12,502,382, issued on Dec. 23, was assigned to INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris), Universite Paul Sabatier Toulouse III (Toulouse, France) and Icahn School of Medicine at Mount Sinai.

"EPAC1 inhibitors for the treatment of idiopathic pulmonary fibrosis" was invented by Malik Bisserier (New York), Frank Lezoualc'h (Toulouse, France) and Lahouaria Hadri (New York).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to the treatment of idiopathic pulmonary fibrosis. Today, there is no cure for IFF. The inventors showed that EPAC1 inhibitors, in particular CE3F4 and AM-001, represent a promising ...